Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1988 Aug;62(8):2614–2621. doi: 10.1128/jvi.62.8.2614-2621.1988

Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

T Sairenji 1, G Bertoni 1, M M Medveczky 1, P G Medveczky 1, Q V Nguyen 1, R E Humphreys 1
PMCID: PMC253691  PMID: 2839689

Abstract

Antibody-mediated inhibition of Epstein-Barr virus (EBV) release from the EBV-productive cell lines P3HR-1 and B95-8 was probed with two monoclonal antibodies (MAbs), 72A1 and 2L10, which immunoprecipitated the same EBV membrane antigen (MA) gp350/220 found with the 1B6 MAb with which inhibition of EBV release from P3HR-1 cells was first described. These three MAbs were not equivalent in either MA reactivities or functional effects, reflecting the variable expression of different epitopes of gp350/220. 1B6 recognized MA on P3HR-1 cells, which expressed predominately the gp220 form of MA. 1B6 did not recognize (or barely recognized) a determinant on B95-8 cells. MAbs 2L10 and 72A1 reacted as well with B95-8 cells as they did with P3HR-1 cells. MAbs 1B6 and 2L10 neutralized neither P3HR-1 nor B95-8 virus, but 72A1 neutralized both viruses. MAbs 1B6 and 72A1 inhibited P3HR-1 virus release, as measured by the assay for infectious virus and by DNA hybridization analysis of released virus, but 2L10 had no such activity. 72A1 (but not 1B6) inhibited release of EBV from B95-8 cells. These experiments pointed to the presence of three different epitopes on gp350/220, identified with the respective MAbs and having varying involvement in virus neutralization and virus release inhibition.

Full text

PDF
2614

Images in this article

2616Image
on p.2616
2617Image
on p.2617
2618Image
on p.2618
2619Image
on p.2619

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beisel C., Tanner J., Matsuo T., Thorley-Lawson D., Kezdy F., Kieff E. Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene. J Virol. 1985 Jun;54(3):665–674. doi: 10.1128/jvi.54.3.665-674.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bornkamm G. W., Delius H., Zimber U., Hudewentz J., Epstein M. A. Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs. J Virol. 1980 Sep;35(3):603–618. doi: 10.1128/jvi.35.3.603-618.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Edson C. M., Thorley-Lawson D. A. Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences. J Virol. 1981 Jul;39(1):172–184. doi: 10.1128/jvi.39.1.172-184.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Edson C. M., Thorley-Lawson D. A. Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus. J Virol. 1983 May;46(2):547–556. doi: 10.1128/jvi.46.2.547-556.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gardella T., Medveczky P., Sairenji T., Mulder C. Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. J Virol. 1984 Apr;50(1):248–254. doi: 10.1128/jvi.50.1.248-254.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Henle W., Henle G., Zajac B. A., Pearson G., Waubke R., Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science. 1970 Jul 10;169(3941):188–190. doi: 10.1126/science.169.3941.188. [DOI] [PubMed] [Google Scholar]
  7. Hinuma Y., Konn M., Yamaguchi J., Wudarski D. J., Blakeslee J. R., Jr, Grace J. T., Jr Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol. 1967 Oct;1(5):1045–1051. doi: 10.1128/jvi.1.5.1045-1051.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hoffman G. J., Lazarowitz S. G., Hayward S. D. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980 May;77(5):2979–2983. doi: 10.1073/pnas.77.5.2979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hummel M., Thorley-Lawson D., Kieff E. An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200). J Virol. 1984 Feb;49(2):413–417. doi: 10.1128/jvi.49.2.413-417.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lin J. C., Raab-Traub N. Two strains of Epstein-Barr virus (B95-8 and a P3HR-1 subclone) that lack defective genomes induce early antigen and cause abortive infection of Raji cells. J Virol. 1987 Jun;61(6):1985–1991. doi: 10.1128/jvi.61.6.1985-1991.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Luka J., Chase R. C., Pearson G. R. A sensitive enzyme-linked immunosorbent assay (ELISA) against the major EBV-associated antigens. I. Correlation between ELISA and immunofluorescence titers using purified antigens. J Immunol Methods. 1984 Feb 24;67(1):145–156. doi: 10.1016/0022-1759(84)90093-0. [DOI] [PubMed] [Google Scholar]
  12. Miller G., Heston L., Countryman J. P3HR-1 Epstein-Barr virus with heterogeneous DNA is an independent replicon maintained by cell-to-cell spread. J Virol. 1985 Apr;54(1):45–52. doi: 10.1128/jvi.54.1.45-52.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Miller G., Heston L., Hoffman G. Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody. Infect Immun. 1982 Sep;37(3):1028–1031. doi: 10.1128/iai.37.3.1028-1031.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Miller G., Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A. 1973 Jan;70(1):190–194. doi: 10.1073/pnas.70.1.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Miller G., Robinson J., Heston L., Lipman M. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A. 1974 Oct;71(10):4006–4010. doi: 10.1073/pnas.71.10.4006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mueller-Lantzsch N., Georg-Fries B., Herbst H., zur Hausen H., Braun D. G. Epstein-Barr virus strain- and group-specific antigenic determinants detected by monoclonal antibodies. Int J Cancer. 1981 Sep 15;28(3):321–327. doi: 10.1002/ijc.2910280311. [DOI] [PubMed] [Google Scholar]
  17. Nemerow G. R., Mold C., Schwend V. K., Tollefson V., Cooper N. R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987 May;61(5):1416–1420. doi: 10.1128/jvi.61.5.1416-1420.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. North J. R., Morgan A. J., Epstein M. A. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. Int J Cancer. 1980 Aug;26(2):231–240. doi: 10.1002/ijc.2910260216. [DOI] [PubMed] [Google Scholar]
  19. PULVERTAFT J. V. A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE. J Clin Pathol. 1965 May;18:261–273. doi: 10.1136/jcp.18.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Qualtiere L. F., Chase R., Pearson G. R. Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein. J Immunol. 1982 Aug;129(2):814–818. [PubMed] [Google Scholar]
  21. Rabson M., Gradoville L., Heston L., Miller G. Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J Virol. 1982 Dec;44(3):834–844. doi: 10.1128/jvi.44.3.834-844.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sairenji T., Hinuma Y. Assay of Epstein-Barr virus by immunofluorescence. Gan. 1973 Dec;64(6):633–636. [PubMed] [Google Scholar]
  23. Sairenji T., Hinuma Y. Inhibitory effect of adult bovine serum on release of infectious Epstein-Barr virus from a virus-carrier cell line. J Natl Cancer Inst. 1975 Aug;55(2):339–343. [PubMed] [Google Scholar]
  24. Sairenji T., Hinuma Y. Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye. Int J Cancer. 1980 Sep 15;26(3):337–342. doi: 10.1002/ijc.2910260313. [DOI] [PubMed] [Google Scholar]
  25. Sairenji T., Hinuma Y., Sekizawa T., Yoshida M. Appearance of early and late components of Epstein-Barr virus-associated membrane antigen in Daudi cells superinfected with P3HR-1 virus. J Gen Virol. 1978 Jan;38(1):111–120. doi: 10.1099/0022-1317-38-1-111. [DOI] [PubMed] [Google Scholar]
  26. Sairenji T., Reisert P. S., Spiro R. C., Connolly T., Humphreys R. E. Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen. J Exp Med. 1985 May 1;161(5):1097–1111. doi: 10.1084/jem.161.5.1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sairenji T., Sullivan J. L., Humphreys R. E. Complement-dependent, Epstein-Barr virus-neutralizing antibody appearing early in the sera of patients with infectious mononucleosis. J Infect Dis. 1984 May;149(5):763–768. doi: 10.1093/infdis/149.5.763. [DOI] [PubMed] [Google Scholar]
  28. Strnad B. C., Schuster T., Klein R., Hopkins R. F., 3rd, Witmer T., Neubauer R. H., Rabin H. Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen. J Virol. 1982 Jan;41(1):258–264. doi: 10.1128/jvi.41.1.258-264.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tanner J., Weis J., Fearon D., Whang Y., Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987 Jul 17;50(2):203–213. doi: 10.1016/0092-8674(87)90216-9. [DOI] [PubMed] [Google Scholar]
  30. Thorley-Lawson D. A., Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307–5311. doi: 10.1073/pnas.77.9.5307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Thorley-Lawson D. A., Poodry C. A. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol. 1982 Aug;43(2):730–736. doi: 10.1128/jvi.43.2.730-736.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES